Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 02:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
150 IU vs. 225 IU FSH in Normal Responders: The OPTIMAL-DOSE Trial
NCT07346235 · American Hospital 2 Kosovo · PHASE3 · withdrawn · last registry update 2026-10-29 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Ethics approval was not obtained. The study was withdrawn before any participants were enrolled.” | – | Registry record, American Hospital 2 Kosovo |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against LHCGR within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-19Phase 3 first posted: Assistance Publique - Hôpitaux de Paris, Verapamil 120 Mg/24 Hours Oral Capsule, Extended Release + blood sampling (NCT07880769)
- 2026-09-11Phase 3 first posted: Fundación para la Investigación del Hospital Clínico de Valencia, Human chorionic gonadotropin (hCG) + Follitropin delta (NCT07816562)
- 2026-03-24Also stopped (terminated): Masonic Cancer Center, University of Minnesota, Ruxolitinib 10 MG Oral Tablet + hCG (NCT05123040)
- 2026-01-14Phase 3 first posted: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Follitropin alfa/lutropin alfa (MBJ-0011) + hMG (NCT07340827)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision